{"prompt": "['APPENDIX III: AMC DATA AND SAFETY MONITORING PLAN', '(Version 6.0', 'March 17, 2017)', 'Monitoring the Progress of Trials and the Safety of Participants', 'All AMC protocols that collect safety data follow the National Cancer Institute (NCI), Cancer', 'Therapy Evaluation Program (CTEP) Guidelines: Adverse Event Reporting Requirements', \"http://ctep.cancer.gov/guidelines/index.html). All adverse events that meet the NCI's expedited\", 'reporting requirements are reported to the Investigational Drug Branch (IDB) of the NCI via the', 'CTEP Adverse Event Reporting System (CTEP-AERS) web application. All expedited adverse', 'event reports are also required to be submitted to the local Institutional Review Board (IRB) of the', 'reporting institution. If NCI holds the IND or no IND is required for a study, the AMC site reports', 'serious adverse events directly to the AMC Operations and Data Management Center (ODMC) via', 'CTEP-AERS; expedited reporting via AdvantageEDC/Advantage eClinical may be permitted for', 'select commercial agent studies per protocol requirements. In some instances, the AMC sites may', 'report serious adverse events directly to a commercial sponsor holding the IND, who will then', 'report the event to the AMC ODMC. Most AMC protocols require sites to report all serious', 'adverse events via CTEP-AERS and the AMC ODMC to forward a copy of the report to the', 'sponsor. The AMC QDMC also distributes all IND safety reports to all investigators upon receipt,', 'and makes these reports available on the password-protected section of the AMC Operations web', 'site. Unless an AMC protocol specifies an alternate plan for the review and submission of serious', 'adverse events, all serious adverse events received by the AMC ODMC will be reviewed by the', 'AMC Medical Monitor at the AMC ODMC. For protocols for which the IDB does not have an', 'assigned drug monitor to review serious adverse event reports, in the event of disagreement', 'between the reporting physician and the AMC Medical Monitor regarding the attribution of the', 'event to the investigational agent(s) (i.e., determination of whether the relationship is unrelated,', 'unlikely, possible, probable, or definite), the AMC Medical Monitor will provide the final', 'determination of the relationship.', 'The AMC ODMC provides listings of all reported adverse events and serious adverse events to', 'the Protocol Chair and Co-chair(s) for review on a regular basis. The AMC ODMC compiles these', 'events in a tabular format and posts them on the password-protected section of the AMC web site', 'where these reports are updated nightly. The AMC web site is accessible to all AMC investigators,', 'co-investigators, and their staff. Email notification that this information is available on the web', 'site will be sent to all site PIs. It is the responsibility of each site to provide this information to', 'their respective IRBs, if required by their IRB. For blinded studies, the serious adverse events are', 'reviewed and tabulated without treatment assignment. The AMC Medical Monitor will review', 'listings of all reported adverse events on a quarterly basis for safety concerns.', 'Accrual summaries for each AMC trial are updated nightly on the password-protected section of', 'the AMC web site. The progress of each AMC trial is reviewed regularly by the Protocol Chair', 'and also by the appropriate disease-oriented Working Group during scheduled conference calls.', 'For phase I dose escalation trials, dose escalation (or dose de-escalation) is based on the rules in', 'the protocol and the Protocol Chair, AMC Medical Monitor, and Group Statistician determine', 'whether these criteria have been met. For phase II trials, stopping the trial for toxicity or efficacy,', 'or suspending enrollment pending observation of responses in a multi-stage phase II trial, is based', 'on meeting criteria stated in the protocol, and the Protocol Chair, AMC Medical Monitor, and', 'AMC-S007 (Version 2.0) 20MAR2018', '46', 'NCI Version Date 20MAR2018']['Group Statistician determine whether these criteria have been met.', 'For phase III trials and other select studies requiring additional oversight, the AMC has formed an', 'independent Data and Safety Monitoring Board (DSMB). Voting members of the DSMB are', 'physicians, a statistician, and a patient advocate. All voting members are from outside the AMC.', 'Nonvoting members are the AMC Group Statistician, the protocol statistician, an AMC Operations', 'Center staff member, two representatives (normally a clinician or statistician) from the Office of', 'HIV AIDS Malignancy (OHAM) or from the Cancer Therapy Evaluation Program, Division of', 'Cancer Treatment and Diagnosis, of the National Cancer Institute (NCI). The DSMB reviews', \"AMC phase III studies in accordance with the National Cancer Institute's Policy for Data and\", 'Safety Monitoring. Confidential reports of all phase III trials are prepared by the AMC Group', 'Statistician with support from the AMC ODMC. A written report containing the current status of', 'each trial monitored, and when appropriate, any toxicity and outcome data, are sent to DSMB', 'members by the AMC ODMC within the timelines specified by the DSMB Charter. This report', 'addresses specific toxicity concerns as well as concerns about the conduct of the trial. The report', 'may contain recommendations for consideration by the DSMB concerning whether to close the', 'trial, report the results, or continue accrual or follow-up.', 'The results of each DSMB meeting are summarized in a formal report sent by the DSMB Chair to', 'the Group Chair and AMC ODMC. The DSMB report contains recommendations on whether to', 'close each study reviewed, whether to report the results, and whether to continue accrual or follow-', 'up. A primary recommendation (e.g., continue with no change; recommended or required', 'modification; stop) must be included in the document. The Group Chair is then responsible for', 'notifying the Protocol Chair and relevant Disease-oriented Working Group Chair before the', 'recommendations of the DSMB are carried out. In the unlikely event that the Protocol Chair does', 'not concur with the DSMB, then the NCI Division Director or designee must be informed of the', 'reason for the disagreement. The Study Chair, relevant Disease-oriented Working Group Chair,', 'Group Chair, DSMB Chair, and NCI Division Director or designee will be responsible for reaching', 'a mutually acceptable decision about the study. CTEP approval of a formal amendment will be', 'required prior to any implementation of a change to the study.', 'Following a DSMB meeting, a summary of the serious adverse events reported to the DSMB is', \"posted to the AMC web site. It is each site's responsibility for conveying this information to its\", 'IRB.', 'Plans for Assuring Compliance with Requirements Regarding the Reporting of Adverse', 'Events (AE)', \"For trials monitored by the NCI's Clinical Data Update System (CDUS), adverse event\", \"information is transmitted electronically to NCI on a quarterly basis. For trials monitored by NCI's\", 'Clinical Trials Monitoring Service (CTMS), adverse event information is transmitted', 'electronically to NCI every two weeks.', 'The Protocol Chair, AMC Group Chair, and the AMC ODMC share responsibility in assuring that', 'participating investigators comply with the protocol requirements for adverse event reporting. All', 'AMC investigators certify compliance with NCI and FDA requirements for adverse event', 'reporting by signing the AMC Adherence Statement for site membership, the protocol signature', 'page for each protocol active at the site, and Form FDA-1572 for CTEP investigator registration', 'and IND studies sponsored by AMC investigators. Investigators are responsible for identifying', 'and reporting all adverse events to the AMC ODMC, CTEP-AERS, and/or sponsors according to', 'AMC-S007 (Version 2.0) 20MAR2018', '47', 'NCI Version Date 20MAR2018']['the protocol requirements, and assuring compliance with reporting to the local IRB. Protocol', 'compliance with adverse event reporting requirements is assessed by the AMC ODMC during', \"routine site audits by reviewing the site's source documentation.\", 'The data entry system used for AMC studies, AdvantageEDC/Advantage eClinical (a web-based', 'data entry and enrollment system), is programmed to notify the site investigator, protocol chair,', 'AMC Medical Monitor, and AMC ODMC via email in the event that a site reports an adverse', 'event that meets expedited reporting criteria to NCI and/or FDA. If the site does not follow with', 'an expedited report, the AMC ODMC contacts sites to request compliance with reporting', 'requirements. Additionally, the protocol chair, AMC ODMC, and the AMC Medical Monitor', 'review reported adverse events on a routine basis to identify adverse events reported by sites that', 'require expedited reporting. The Protocol Chair, AMC Group Chair, and IND sponsors have', 'general oversight for assuring that routine and expedited adverse reporting requirements are met', 'by the responsible parties.', 'Plans for Assuring that any Action Resulting in a Temporary or Permanent Suspension of', 'an NCI-Funded Clinical Trial is Reported to the NCI Grant Program Director Responsible', 'for the Grant', 'In the event that termination of the trial or major modification to the protocol is under', 'consideration, the Protocol Chair will convene the AMC Data Coordinator and Disease-oriented', 'Working Group Chair by conference call to discuss the options. For phase I and II trials, the', 'Protocol Chair also has the option of asking the DSMB to review the study. The AMC ODMC will', 'inform the CTEP Protocol Information Office (PIO) when studies are temporarily or permanently', 'closed. The Cancer Treatment and Evaluation Program (CTEP) of the National Cancer Institute', '(NCI) must approve all protocol amendments prior to distributing to the AMC sites.', 'Plans for Assuring Data Accuracy and Protocol Compliance', 'All study data for AMC clinical trials are entered directly by AMC clinical site staff into', 'AdvantageEDC/Advantage eClinical. During data entry, the system performs validation checks on', 'many fields and performs consistency checks between select fields. Range checks are placed on', 'each field to eliminate entry of out-of-range values. Edit check programs are run on the database', 'on a set schedule to identify and resolve inconsistencies between forms or data collected at', 'different points in time. AMC ODMC staff routinely interacts with site staff to resolve any data', 'problems.', 'In accordance with NCI guidelines, the AMC ODMC conducts audits at the AMC sites to evaluate', 'compliance with regulatory issues, and to review data for specific cases by checking source', 'documents. These reports are sent to the site Principal Investigator and to the NCI. In the event', 'that major violations are identified, sites are asked to provide a written corrective and preventative', 'action plan to correct deficiencies. If needed, a repeat site audit is conducted. In the event that a', 'site does not correct deficiencies in a pre-determined time frame, the AMC Executive Committee', 'has the option of taking action against the site. Possible actions include, but are not limited to,', 'suspending enrollment of new patients to AMC trials until deficiencies are corrected;', 'recommending a decrease in funding to the site; and requiring specific training for site', 'investigators or staff members.', 'AMC-S007 (Version 2.0) 20MAR2018', '48', 'NCI Version Date 20MAR2018']", "completion": ""}